# Full Title: Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi

- 3 Short Title: Cost-effectiveness Analysis of Rotavirus Vaccination in Malawi
- 4
- 5 Authors: Catherine Wenger<sup>1</sup>, Ernest O. Asare<sup>1,2</sup>, Jiye Kwon<sup>1,2</sup>, Xiao Li<sup>2,3</sup>, Edson
- 6 Mwinjiwa<sup>4,5,6</sup>, Jobiba Chinkhumba<sup>4,6</sup>, Khuzwayo C. Jere<sup>4,5,7,8</sup>, Daniel Hungerford<sup>4,7</sup>,
- 7 Nigel A. Cunliffe<sup>4,7</sup>, A. David Paltiel<sup>2,9</sup>, Virginia E. Pitzer<sup>1,2</sup>

#### 8 Affiliations:

- <sup>1</sup> Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New
   Haven, CT, United States
- <sup>2</sup> Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT, United
   States
- <sup>3</sup> Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of
   Antwerp, Belgium
- <sup>4</sup> NIHR Global Health Research Group on Gastrointestinal Infections, University of Liverpool, Liverpool,
- 16 Merseyside, UK
- 17 <sup>5</sup> Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi
- <sup>6</sup> School of Global and Public Health, Kamuzu University of Health Sciences, Blantyre, Malawi
- <sup>7</sup> Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and
- 20 Ecological Sciences, University of Liverpool, Liverpool, UK
- <sup>8</sup> Department of Medical Laboratory Sciences, Faculty of Biomedical Sciences and Health Profession,
- 22 Kamuzu University of Health Sciences, Blantyre, Malawi
- <sup>9</sup> Department of Health Policy & Management, Yale School of Public Health, Yale University, New Haven,
- 24 CT, United States

25 **Abstract:** Rotavirus is the leading cause of severe diarrhea among children under five

- worldwide, especially in low- and middle-income countries (LMICs). Although
- 27 vaccination is the best strategy for preventing rotavirus infection, obstacles leading to
- 28 poor vaccine effectiveness undermine its impact in LMICs. This study aimed to evaluate
- 29 the impact and cost-effectiveness of the current two-dose Rotarix vaccine schedule in
- 30 Malawi compared to two alternative vaccine delivery schedules and a next-generation
- 31 neonatal vaccine (RV3-BB) from 2025-2034. The cost-effectiveness of rotavirus vaccine
- 32 strategies in Malawi was evaluated from both the government and societal perspectives
- 33 using estimates of moderate-to-severe and non-severe rotavirus cases derived from a
- 34 mathematical model of rotavirus transmission dynamics and published estimates of
- 35 health-seeking behaviors and costs as inputs. A probabilistic sensitivity analysis was
- 36 performed to evaluate the robustness of our results to parameter uncertainty. Over a
- 37 ten-year time horizon, the current two-dose strategy was predicted to avert over 1.5
- 38 million cases and 90,000 disability-adjusted life-years (DALYs) and cost \$104.87 per
- 39 DALY averted compared to no vaccination from the government perspective. Adding a
- 40 third dose at 14 weeks could avert about 1 million more cases and cost \$5 million more
- 41 than the current strategy. The neonatal RV3-BB vaccine could avert 1.1 million cases
- 42 and 41,000 DALYs due to rotavirus and save about \$3.7 million compared to the current
- 43 strategy. The current rotavirus vaccine program in Malawi is cost-effective and saves
- 44 lives compared to no vaccination. However, adding a third dose is likely to be cost-
- 45 effective at a willingness to pay (WTP) of \$138.38 per DALY averted, while switching to
- 46 the neonatal RV3-BB vaccine when available is likely to be cost-effective at a WTP
- 47 above \$45.89 per DALY averted.

It is made available under a CC-BY 4.0 International license .

## 48 Introduction

49	Rotavirus causes non-severe to severe gastroenteritis in people of all ages and
50	is the leading cause of deaths related to diarrhea globally(1, 2). Children less than 5
51	years old in low- and middle-income countries (LMICs) are most at risk for both getting
52	infected with and dying from rotavirus-associated gastroenteritis (RVGE)(2, 3). Such
53	high rates of disease in young and vulnerable populations lead to substantial years lost
54	to disability and death, with over 6,000 disability-adjusted life-years (DALYs) per
55	100,000 children <5 years old attributed to RVGE occurring in sub-Saharan Africa every
56	year(4).
57	Although there are generic approaches to preventing diarrheal disease in
58	children, the only rotavirus-specific intervention currently available is vaccination.
59	Rotavirus vaccines have been licensed since 2006, and in 2009, the World Health
60	Organization (WHO) recommended that countries worldwide add rotavirus vaccines to
61	their routine immunization programs (5). Gavi, the Vaccine Alliance, has subsidized
62	rotavirus vaccine costs in eligible countries, with the two-dose, live-oral monovalent
63	Rotarix (RV1; GlaxoSmithKline; Rixensart, Belgium) vaccine being the most widely used
64	option(6, 7). However, rotavirus vaccine efficacy and effectiveness tend to be lower in
65	LMICs due to multiple factors that might lead to poor seroconversion, such as
66	interference from co-administered oral poliovirus vaccines (OPVs), maternal antibodies,
67	and malnutrition(8).
68	Malawi was one of the first LMICs to incorporate the two-dose Rotarix vaccine
69	schedule into its Expanded Program of Immunization (EPI). Since the vaccine was

69 schedule into its Expanded Program of Immunization (EPI). Since the vaccine was

<sup>70</sup> introduced in 2012, the proportion of hospital admissions due to diarrheal disease

It is made available under a CC-BY 4.0 International license .

71 caused by rotavirus has declined by 30% due to the prevention of severe disease in the 72 first year of life(9, 10). Still, the overall vaccine impact has been modest and plateaued 73 in recent years (9, 10). A previous model that evaluated vaccine strategies in Malawi 74 estimated that adding a third dose to the current two-dose schedule could modestly 75 increase vaccine impact(11). However, it is important to consider the cost-effectiveness 76 and optimal timing of the third dose. Alternatively, a recent phase 2 vaccine trial 77 conducted in Malawi suggests that it may be possible to achieve better seroconversion 78 and earlier protection against rotavirus using a new oral neonatal vaccine (RV3-BB) 79 administered in three doses at birth, 6, and 10 weeks of age(12). Malawi's robust 80 immunization program, early adoption of the rotavirus vaccine, and experience with low 81 vaccine effectiveness make it an ideal case study to evaluate the impact of new vaccine 82 strategies on disease burden and healthcare spending.

83 The primary aim of this study was to identify the optimal rotavirus vaccine 84 schedule for Malawi using a transmission dynamic model of vaccine impact and a cost-85 effectiveness model with a probabilistic sensitivity analysis over a ten-year time horizon 86 (2025-2034). We compared the cost and performance of five different vaccination 87 selection and dosing strategies, which allowed us to ask important guestions for three 88 different decision-making scenarios. First, in the event of a change in availability, 89 funding, or priority, how does any vaccination strategy compare to no rotavirus 90 vaccination? Second, how might decision-makers choose between currently available 91 vaccine options? And finally, how might the future introduction of the RV3-BB neonatal 92 vaccine change this assessment? We evaluated each strategy's cost from the 93 government and societal perspectives and its health outcomes in averting DALYs. The

It is made available under a CC-BY 4.0 International license .

results of this study can help decision-makers in Malawi identify the optimal vaccine and
corresponding dosing schedule and set price thresholds for the potential future adoption
of the RV3-BB neonatal vaccine.

#### 97 Methods

98 Transmission Dynamic Model

99 A transmission dynamic model developed by Pitzer et al. to simulate RVGE 100 incidence in low-income settings provided the epidemiological outputs, including the 101 number of rotavirus cases by severity (moderate-to-severe and non-severe) and age 102 (by year under 5) and the number of doses administered(11). The transmission model 103 had disease states for vaccinated and unvaccinated individuals stratified by age group. 104 We assumed that disease severity decreases with subsequent infections and that 105 maternal, natural, and vaccine-induced immunity wanes over time(11). The model 106 structure and other details are in the Supplementary Materials. 107 We used previously estimated model parameters when the model was fitted to 108 rotavirus surveillance data obtained from Blantyre for the entirety of Malawi (Table 109 S1)(11). The proportion of individuals responding to each dose of the vaccine was 110 estimated using vaccine immunogenicity data from clinical trials in Malawi for both 111 Rotarix and RV3-BB vaccines using the formulation proposed by Pitzer et al.(11-13). 112 We randomly generated 1000 samples from the key model parameter sets, assuming a 113 beta distribution, to project RVGE cases over ten years. For the fitted parameters ( $R_0$ , b,  $\phi$ , h,  $\omega_v$ ), we sampled within the 95% credible intervals (Table S1). For the estimated 114 115 parameters ( $S_{C1}$ ,  $S_{C2}$ ,  $S_{C3}$ ,  $S_{C2n}$ ,  $S_{C3n}$ ), we sampled within 20% uncertainty (±20%)

It is made available under a CC-BY 4.0 International license .

around the point estimates (Table S1). For this simulation, we utilized demographic datafor Malawi.

118 Strategies & Outcomes

119 We evaluated five vaccine strategies over a 10-year time horizon from 2025 to 120 2034, including: (1) no vaccination; (2) two doses of Rotarix administered at 6 and 10 121 weeks (current strategy); (3) three doses of Rotarix administered at 6, 10, and 14 122 weeks; (4) three doses of Rotarix administered at 6, 10, and 40 weeks; and (5) three 123 doses of the neonatal RV3-BB vaccine administered at 1, 6, and 10 weeks. We 124 considered three-dose Rotarix schedules because they coincide with other routine 125 vaccines, the 6/10/14 schedule reflecting the dosing schedule of other rotavirus 126 vaccines that many countries use, and the 6/10/40 schedule simulating adding a 127 booster dose of Rotarix to the current strategy. 128 The primary analysis considered all five options. Recognizing that the RV3-BB 129 vaccine is not yet available, we also evaluated whether Malawi should end vaccination, 130 remain with the current two-dose Rotarix vaccine schedule, or add a third dose to the

131 schedule at 14 weeks or 40 weeks of age. For each strategy, outputs from the dynamic

132 model included the number of vaccine doses administered, moderate-to-severe RVGE

133 cases, and non-severe RVGE cases per year for children <5 years old across 1000

134 simulations.

135 Economic Evaluation Model

The probability tree in Figure 1 depicts the various possible treatment paths for children with moderate-to-severe and non-severe RVGE and the costs incurred at the government and household levels. Treatment and survival probabilities determined the

#### It is made available under a CC-BY 4.0 International license .

- 139 proportion of individuals with RVGE who travel each treatment pathway. Those with
- 140 non-severe RVGE were assumed to either seek outpatient care or no care at all, and
- 141 we assumed all non-severe RVGE cases survive. Those with moderate-to-severe
- 142 RVGE sought care at higher rates and were assumed to receive inpatient care more
- 143 than outpatient care because of the severity of the disease and in keeping with local
- 144 treatment practices. In addition, cases of moderate-to-severe RVGE may not seek care
- 145 at all, incurring no cost but also having a higher case fatality risk (CFR).

#### 146 Fig 1. Probability tree of seeking treatment for rotavirus-associated

147 gastroenteritis (RVGE). Output from the transmission dynamic model on the number of 148 moderate-to-severe and non-severe RVGE cases was combined with data on the 149 probability of healthcare-seeking and case fatality risks (CFR) (red) and data on the per-150 case cost to the government (blue) and the household (green). Costs from the societal 151 perspective included both government and household costs. All values are further 152 described in Table 1. CFR\*(0,1) represents the probability of dying as an outpatient is 153 some fraction of the inpatient CFR, sampled from a uniform distribution from 0 to 1.

154 Input Parameters & Data

155 Table 1 includes all parameter estimates and uncertainty distributions for the

- 156 input parameters used in the cost-effectiveness analysis. Most parameters were derived
- 157 from secondary sources. Health-seeking probability parameter estimates were extracted
- 158 from a series of related studies conducted in Kenya about the impact of RVGE of
- 159 varying severities on the population and their health-seeking behaviors, as data from
- 160 Malawi was unavailable(14, 15). CFR estimates were derived from a recent systematic
- review that found hospital-based studies reported lower CFRs than community-based
- 162 studies(16). We assumed the outpatient CFR is some fraction of the likelihood of dying
- 163 from moderate-to-severe RVGE when treated as an inpatient. The model parameters
- are further described in the supplemental materials.
- 165

It is made available under a CC-BY 4.0 International license .

#### 166 **Table 1. Input parameters for cost-effectiveness analysis**

Parameter	Estimate	Uncertainty Distribution	Source
Treatment probabilities for moderate-to-severe R	VGE		
Probability of seeking treatment	0.8	Beta(2600,650)	(14)
Probability of not seeking treatment	0.2	1- Beta(2600,650)	(14)
Probability of care - inpatient	0.6	Beta(1432,955)	(14)
Probability of care - outpatient	0.4	1 - Beta(1432,955)	(14)
Probability of death - inpatient (CFR <sub>inpatient</sub> )	0.011	Beta(6.74,606.29)	(16)
Probability of death - outpatient (CFR <sub>outpatient</sub> )	0.0055	CFR <sub>inpatient</sub> *Unif(0,1)	(16)
Probability of death - no treatment (CFR <sub>no treatment</sub> )	0.025	Beta(6.63,258.72)	(16)
Treatment probabilities for non-severe RVGE			
Probability of care - outpatient	0.55	Beta(833,681)	(14)
Probability of no care	0.45	1 - Beta(833,681)	(14)
Probability of death – non-severe	0	Fixed	Assumption
Vaccine-related costs*			
Cost of vaccine (per dose) - Rotarix	1.94 USD	Fixed	(17)
Cost of vaccine (per dose) - Neonatal	1.32 USD	Fixed	(18)
Cost of delivery of vaccine (per dose)	0.58 USD	Fixed	(19)
Cost of switching - Neonatal	1,024,365 USD	Fixed	(20)
Vaccine wastage rate	0.05	Fixed	(21)
Treatment costs*			
Cost of treatment <sup>†</sup> - inpatient, moderate-severe	62.39 USD	Gamma(1.39,43.54)	(22)
Cost of treatment - outpatient, moderate-severe	22.20 USD	Gamma(15.18, 1.46)	(22)
Cost of treatment - outpatient, non-severe	11.10USD	Gamma(7.56,1.47)	(22)
Household cost <sup>‡</sup> - inpatient, moderate-severe	15.20 USD	Gamma(0.81,18.76)	(22)
Household cost - outpatient, moderate-severe	9.44 USD	Gamma(0.79,11.94)	(22)
Household cost - outpatient, non-severe	0.68 USD	Gamma(0.24,2.87)	(22)
Disability-adjusted life-year (DALY) parameters			
DALY weight - moderate-to-severe	0.281	Beta(18.59,47.57)	(22)
DALY weight - non-severe	0.202	Beta(17.96,70.93)	(22)
Duration of infection	6 days	Fixed	(22)
Life expectancy at birth	63 years	Fixed	(23)
Economic evaluation			
1/2 * Gross domestic product (GDP) per capita - Malawi	335 USD	Fixed	(24)
Discount rate	0.03	Fixed	(25)

167 \*All costs are inflated by 3% per year to reflect predicted 2025 prices

<sup>168</sup> <sup>†</sup>Per case costs to the government used in both government and societal perspective analysis

169 <sup>‡</sup>Per case direct and indirect costs (including loss of productivity) to the household used in the societal

170 perspective analysis

It is made available under a CC-BY 4.0 International license .

171

172 DALYs were calculated by summing the years of life lost due to disability (YLDs) 173 and years of life lost due to premature mortality (YLLs)(26). YLDs were calculated by 174 multiplying the number of cases, the duration of infection, and the DALY weight (a 175 guantification of the severity of non-severe or moderate-to-severe rotavirus). The YLLs 176 were calculated using the life expectancy minus the age of death for each age group 177 times the number of deaths proportional to each age group. Treatment probabilities and 178 CFRs were parameterized using beta distributions; shape parameters for each 179 probability and DALY weight were calculated from sample means and standard errors 180 (derived from 95% confidence intervals)(27).

181 The cost of delivery of an individual dose of the rotavirus vaccine included all EPI 182 purchasing and program costs needed to administer a dose, including vaccine delivery, 183 cold chain storage, and personnel costs(19). We assumed this cost was the same for 184 both Rotarix and the neonatal RV3-BB vaccine. We also assumed that the cost of the 185 neonatal vaccine per dose would be \$1.32 based on a study that estimated the optimal 186 cost of goods given the current manufacturing process(18). A 2023 study estimated the 187 cost of switching from Rotarix to the Rotavac rotavirus vaccine in Ghana, and given that 188 Ghana and Malawi both have Rotarix in their routine national immunization programs, 189 the one-time cost of switching was used as the cost of switching to the neonatal vaccine 190 in this analysis (20). We assumed no upfront cost to adding a third dose to the Rotarix 191 schedule given that the health system can already deliver Rotarix. The total cost of 192 vaccination for each strategy was adjusted for 5% vaccine wastage based on a global 193 immunization strategy costing study by Wolfson et al.(21). The analysis was conducted

It is made available under a CC-BY 4.0 International license .

194 from the government perspective using the treatment costs paid by the government per

195 case of RVGE. Analysis from the societal perspective includes the treatment costs to

196 the government, direct treatment costs to the household, and indirect costs of

197 productivity loss, transportation, and food per case of RVGE(22).

198 For all cost data, the sample means and standard deviations (derived from 95%) 199 confidence intervals) were used to calculate the shape and scale parameters for a 200 gamma distribution using the method of moments(27). One-time costs, such as the cost 201 of switching to the neonatal vaccine, and set costs, such as the price of a single dose of 202 the Rotarix vaccine, were fixed. We inflated all cost data by 3% per year to reflect 203 predicted prices in 2025 to match the start of the simulation and converted costs to 204 USD, as necessary. Costs and DALYs were discounted at 3% per year after the start of 205 the simulation, a standard practice when costs and outcomes are used to inform

206 resource allocation decisions(25).

207 S

#### Sensitivity & Scenario Analyses

208 We conducted a probabilistic sensitivity analysis by sampling 1,000 times from 209 the output of the transmission dynamic model (for different parameter sets), the cost 210 distributions, and the event probability distribution. Each simulation produced the cost of 211 vaccination and treatment and a summary of cases, hospitalizations, deaths, and 212 DALYs averted by each strategy compared to the status quo. Incremental costs and the 213 number of DALYs averted by each strategy compared to the status guo for the 1,000 214 simulations were plotted in a cost-effectiveness plane that illustrates the cost-215 effectiveness of each strategy relative to the comparator strategy. Incremental cost-216 effectiveness ratios (ICER) were calculated using the equation ICER = Difference in

It is made available under a CC-BY 4.0 International license .

Cost / Difference in DALYs to demonstrate the efficient use of resources when
compared to a WTP threshold. We used a net benefits framework to portray the
robustness of the model's findings in the face of parameter uncertainty. Specifically, we
reported the probability that a given strategy would be cost-effective (i.e., the
percentage of simulations in which it yielded the highest net benefit) across a range of
WTP thresholds (28).

Since the RV3-BB vaccine is not on the market yet, there is an opportunity to evaluate the range of prices over which the neonatal vaccine strategy might be costeffective. We used a one-way threshold analysis to determine the price per dose at which the neonatal vaccine would cease to be cost-effective compared to the current two-dose Rotarix vaccine strategy and the optimal three-dose strategy. Without an established WTP threshold for Malawi, we used 0.5x GDP per capita, which will likely be around \$335 in 2025(24, 29).

230 Results

231 Over the ten-year simulation period (2025-2034), rotavirus vaccination programs 232 were predicted to avert at least 1.5 million cases, 120,000 hospitalizations, 90,000 233 DALYs, and 3,000 deaths caused by RVGE compared to no vaccination, regardless of 234 the vaccine type, number of doses, or immunization schedule (Fig 2, Table S2). The 235 model suggested the current Rotarix strategy (6/10 schedule) averted over 1.5 million 236 cases and 3,000 deaths compared to no vaccination. When a third dose was added to 237 the current schedule, the 6/10/14 schedule averted an additional estimated 1 million 238 cases and 1200 deaths compared to the 6/10 strategy, while the 6/10/40 schedule 239 averted 1 million cases and only 800 deaths (Table S3). The neonatal RV3-BB vaccine

It is made available under a CC-BY 4.0 International license .

- 240 led to the greatest estimated reduction in the burden of RVGE overall across all health
- outcomes evaluated, averting 2.5 million cases and 4,200 deaths compared to no
- vaccination and 1.1 million cases, 40,000 DALYs, and 1,200 deaths compared to the
- 243 current two-dose Rotarix strategy.

Fig 2. Total cases, hospitalizations, DALYs, and deaths for each vaccine strategy
from 2025-2034. Strategies depicted: No vaccination (dark gray), Neonatal RV3-BB
1/6/10 (orange), Rotarix 6/10 (red), Rotarix 6/10/14 (blue), Rotarix 6/10/40 (light gray).
Violin plots show the distribution of the total number of health outcomes for each
simulation of each strategy. The lines connect simulations using the same sampled
parameter sets.

- 250
- 251 The predicted healthcare expenditure for the treatment of RVGE with no vaccine
- strategy in effect was the cheapest strategy, totaling \$89.7 million over ten years from
- the government perspective (Table 2). We estimated that the current two-dose Rotarix
- vaccine strategy costs about \$99.6 million, and the 6/10/14 and 6/10/40 Rotarix
- schedules cost about \$5.3 and \$5.8 million more than the current strategy, respectively.
- We also estimated that the intervention cost of the Rotarix 6/10 strategy is cheaper than
- the neonatal strategy, but the treatment costs are much higher (Table 2). While the
- neonatal strategy cost more than no vaccination, it was cost-saving compared to all
- 259 Rotarix strategies, saving about \$3.7 and \$4.8 million in total costs compared to the
- 260 current two-dose schedule from the government and societal perspectives, respectively
- 261 (Table 2). From the societal perspective, all vaccine strategies cost about \$8-10 million
- more, while no vaccination costs about \$11 million more compared to the government
- 263 perspective.

#### Table 2. The ten-year cost of each vaccine strategy and the difference in total cost compared to the current Rotarix 6/10 strategy from the government and societal perspectives.

Cost by Vaccine Schedule (in Millions)								
		Government Perspective				Societal Perspective		
Strategy	Intervention Cost	Treatment Cost	Total Cost	Cost Difference*	Intervention Cost	Treatment Cost**	Total Cost	Cost Difference*
No vaccine	\$0.0	\$89.7	\$89.7	-\$9.9	\$0.0	\$101.1	\$101.1	-\$7.4
Neonatal 1/6/10	\$29.2	\$66.7	\$95.9	-\$3.7	\$29.2	\$74.5	\$103.7	-\$4.8
Rotarix 6/10	\$25.1	\$74.5	\$99.6		\$25.1	\$83.4	\$108.5	
Rotarix 6/10/14	\$37.7	\$67.2	\$104.9	\$5.3	\$37.7	\$74.9	\$112.6	\$4.1
Rotarix 6/10/40	\$37.7	\$67.7	\$105.4	\$5.8	\$37.7	\$75.7	\$113.4	\$4.9

Costs reflect 2025 USD

\*relative to status quo (Rotarix 6/10)

\*\*Including direct and indirect household costs

It is made available under a CC-BY 4.0 International license .

267 268	Compared to the current 6/10 Rotarix strategy, we estimated the 6/10/14
269	schedule averted more moderate-to-severe RVGE cases and fewer non-severe cases
270	than the 6/10/40 schedule, leading to \$500,000 in higher treatment costs for the 6/10/40
271	strategy (Table 2, Table S3). Nevertheless, the three-dose Rotarix schedules were
272	strongly dominated by the neonatal RV3-BB vaccine (meaning they were more
273	expensive and averted fewer DALYs) (Table 3). The model estimated that the RV3-BB
274	vaccine had an ICER of \$45.89 per DALY averted compared to no vaccination from the
275	government perspective and, therefore, is likely to be highly cost-effective (Table 3).
276	Viewed from the societal perspective, the RV3-BB vaccine had an ICER of \$19.25 per
277	DALY averted (Table S5).

# Table 3. DALYs averted and incremental cost-effectiveness ratios for all vaccine strategies compared to the current Rotarix 6/10 schedule from the government perspective.

		Goverr	nment perspect	ive	
Strategy	Cost (millions)	DALYs (thousands)	Incremental Cost (millions)	DALYs Averted (thousands)	ICER (\$/DALY averted) vs next best alternative
No vaccine	\$89.70	358.1			
Neonatal 1/6/10	\$95.90	223.0	\$6.2	135.1	\$45.89
Rotarix 6/10	\$99.60	263.7	\$3.7	-40.70	Dominated
Rotarix 6/10/14	\$104.90	225.4	\$9.0	-2.40	Dominated
Rotarix 6/10/40	\$105.40	236.2	\$9.5	-13.20	Dominated

Cost-Effectiveness Comparison of All Vaccine Strategies

Costs reflect 2025 USD

In conformity with accepted practice, all incremental costs and DALYs averted are computed compared to the next smallest, non-dominated strategy

It is made available under a CC-BY 4.0 International license .

281 282	Understanding that RV3-BB is not yet on the market, we conducted the cost-
283	effectiveness analysis a second time with that option removed. The Rotarix 6/10
284	strategy had an estimated ICER of \$104.87 per DALY averted compared to no
285	vaccination (Table 4). The ICER for the Rotarix 6/10/14 schedule compared to the 6/10
286	strategy was \$138.38 per DALY averted from the government perspective. From the
287	societal perspective, the ICERs were \$78.39 and \$107.05 per DALY averted for the
288	Rotarix 6/10 and 6/10/14 strategies, respectively (Table S6). The Rotarix 6/10/40
289	strategy was once again strongly dominated (Table 4, Table S6).

## Table 4. DALYs averted and incremental cost-effectiveness ratios for Rotarix vaccine strategies compared to no vaccination from the government perspective.

Government perspective				_	
Strategy	Cost (millions)	DALYs (thousands)	Incremental Cost (millions)	DALYs Averted (thousands)	ICER (\$/DALY averted) vs next best alternative
No vaccine	\$89.70	358.1			
Rotarix 6/10	\$99.60	263.7	\$9.9	94.4	\$104.87
Rotarix 6/10/14	\$104.90	225.4	\$5.3	38.3	\$138.38
Rotarix 6/10/40	\$105.40	236.2	\$0.5	-10.8	Dominated

Cost-Effectiveness Comparison of Available Vaccine Strategies

Costs reflect 2025 USD

In conformity with accepted practice, all incremental costs and DALYs averted are computed compared to the next smallest, non-dominated strategy

It is made available under a CC-BY 4.0 International license .

293	When we conducted a	probabilistic sensitivity	v analvsis. i	in 81% of the PSA
			,	

- iterations, the neonatal vaccine yielded lower costs and fewer DALYs than the Rotarix
- 295 6/10 schedule. In other words, the neonatal vaccine was cost-saving-denoted by points
- in the lower-right quadrant–81% of the simulations we conducted (Fig 3). We predicted
- that the neonatal vaccine was cost-saving, while the three-dose Rotarix strategies each
- had ICERs exceeding \$130 per DALY averted compared to the status quo (Fig 3). The
- 299 probability of the neonatal vaccine being cost-effective peaked at an estimated 90% at a
- 300 WTP of about \$150 (Fig 4a,b). The model suggested that switching to RV3-BB would be
- 301 optimal at any WTP threshold above \$45 per DALY averted from the government
- 302 perspective (Fig 4b) and would have an 87% probability of being cost-saving compared
- 303 to the status quo from the societal perspective (Fig S3).

304 Fig 3. Cost-effectiveness plane for the cost-effectiveness ratios of the four

305 strategies compared to the current Rotarix 6/10 schedule from the government

306 *perspective.* Points represent the average cost-effectiveness ratio for each strategy.

307 The WTP threshold is \$335 per DALY averted (0.5x Malawi's GDP per capita).

308 Fig 4. Cost-effectiveness acceptability (a) curves and (b) frontier for all strategies

309 and (c) curves and (d) frontier for currently available strategies from the

310 **government perspective.** The vertical green line represents 0.5x Malawi's GDP per 311 capita.

312 No vaccination was estimated to be cost-effective only at very low WTP

313 thresholds from the government's perspective. At a WTP threshold of 0.5x GDP per

- capita (US\$335), the Rotarix 6/10/14 strategy was cost-effective compared to the
- 315 current 6/10 strategy, although all Rotarix strategies were dominated by the RV3-BB
- 316 vaccine. If we exclude the RV3-BB vaccine from the analysis, there was greater
- 317 uncertainty in the preferred strategy at low WTP thresholds (Fig 4c, Fig S4c). The
- 318 Rotarix 6/10/14 schedule had a high probability of being cost-effective at WTP
- 319 thresholds above \$200 per DALY averted, but the simulation distributions suggested the

320 strategies had very similar costs and outcomes (Fig S2). No vaccination was optimal up

to an estimated WTP of about \$105 per DALY averted, Rotarix 6/10 at a WTP between

322 \$105 and \$140, and 6/10/14 at any WTP above \$140 from the government perspective

323 (Fig 4d).

324 The price threshold analysis for RV3-BB revealed that compared to Malawi's

325 current two-dose vaccine strategy and at a WTP threshold equal to 0.5x GDP per

326 capita, the neonatal vaccine was the optimal strategy up to a maximum estimated per-

dose price of \$2.40 (Fig 5a). This price is almost twice the predicted price of one dose

of RV3-BB. Compared to the Rotarix 6/10/14 schedule, the neonatal vaccine was the

optimal strategy up to an estimated per-dose price of \$1.90 (Fig 5b). Even at a WTP of

330 \$10, the neonatal vaccine was optimal up to a price between \$1.50 and \$1.90 per dose,

331 which is still greater than the predicted price.

Fig 3. Sensitivity analyses of the price per dose of the RV3-BB neonatal vaccine
 compared to the current Rotarix schedule and the optimal three-dose Rotarix
 schedule from the government perspective. The Rotarix price remained fixed at
 \$1.94 per dose. The WTP is \$335 per DALY averted.

#### 336 Discussion

337 Despite the introduction of the two-dose Rotarix vaccine into the Malawi national

immunization program over ten years ago, RVGE still poses a substantial burden on the

339 population. This study contributes to the small body of literature evaluating alternative

- 340 rotavirus vaccine strategies to address lower vaccine efficacy in LMICs. Clinical trials
- have suggested that a third dose of Rotarix could improve the seroconversion rate, but
- 342 the potential impact and cost-effectiveness of a third dose are unknown(8).
- 343 Furthermore, the neonatal RV3-BB vaccine, which concluded a phase 3 trial in 2023,
- 344 offers the opportunity to improve seroconversion and immunize neonates before they

It is made available under a CC-BY 4.0 International license .

345 have the chance to become infected as infants. Still, decision-makers need information 346 on the cost of potential vaccination strategies compared to the benefits. Our analysis shows that switching Malawi's EPI rotavirus vaccination strategy from the current two-347 348 dose Rotarix vaccine to the three-dose RV3-BB vaccine with a neonatal schedule might 349 be cost-saving relative to the current vaccination program. Adding a third dose of 350 Rotarix to the schedule at 14 weeks of age (i.e., the same age as a third dose of 351 pentavalent vaccine and OPV) would also likely be cost-effective in the absence of the 352 neonatal vaccine.

353 A 2022 cost-effectiveness study modeled injectable and oral next-generation 354 rotavirus vaccines and found that an injectable Next Generation Rotavirus Vaccine 355 (iNGRV) administered as part of a diphtheria-tetanus-pertussis (DTP)-containing 356 combination would be the most cost-effective strategy in LMICs(30). However, the 357 development of an iNGRV faced recent setbacks; a Phase 3 study of the leading 358 iNGRV candidate ended early after an interim analysis concluded it was no better than 359 the current vaccines on the market(31). Without iNGRVs, the oral RV3-BB was also 360 found to be cost-effective compared to all rotavirus vaccines currently on the market, 361 including Rotarix(30). Other rotavirus vaccination cost-effectiveness studies in Malawi 362 showed results consistent with our findings that the Rotarix two-dose schedule is cost-363 effective. Bar-Zeev et al. conducted a prospective cohort study in 2016 that 364 demonstrated that the two-dose Rotarix schedule is more cost-effective than no 365 vaccination, costing \$19 per DALY averted(22). A 2018 study by Pecenka et al. found 366 Rotarix to be the most cost-effective strategy in Malawi when considering the Rotavac 367 and Rotasiil three-dose schedules, with an ICER of \$7 per DALY averted(19). Our ICER

It is made available under a CC-BY 4.0 International license .

for the two-dose Rotarix vaccine compared to no vaccination is higher than previous
analyses, likely driven by the lower vaccine impact predicted by our transmission model,
which we validated against the observed reduction in RVGE hospitalizations in Blantyre
from 2012 to 2022(9).

372 In Malawi, we estimate that a neonatal rotavirus vaccine program would cost 373 about \$28 million over ten years, including about \$1 million in the first year to switch, but 374 it would save about \$8 million in treatment costs compared to the current vaccine 375 strategy over ten years. Even if the market price of the new RV3-BB vaccine is higher 376 than the projected price of \$1.32, it is still likely to be cost-effective at a WTP of \$335 377 per DALY averted compared to the current vaccine strategy, provided the price per 378 dose is less than \$2.40 with Gavi support. Even when we assume that the societal 379 willingness to pay is low, the projected price of the neonatal vaccine is likely to be 380 comfortably below our estimate of the maximum permissible price.

381 Cost-effectiveness analyses provide a way to evaluate and compare different 382 vaccine strategies, assigning costs per unit benefit to inform decision-making. However, 383 this analysis only captures a few considerations in the decision-making process. While 384 the WTP threshold used in our primary analysis is 0.5x Malawi's GDP per capita 385 (US\$335), the Malawi strategic health plan suggests the government's WTP is between 386 \$3-\$116 per DALY averted(32). Even with this much lower threshold, in all government 387 and societal-perspective scenarios, the Rotarix 6/10 and neonatal RV3-BB 1/6/10 388 vaccine strategies remain cost-effective. From the societal perspective, the Rotarix 389 6/10/14 schedule falls within this range as well. These analyses account for the one-390 time cost of switching to the neonatal vaccine, which we conservatively estimated to be

It is made available under a CC-BY 4.0 International license .

391 \$1 million. In deciding to switch to the neonatal vaccine, Malawi must be willing to pay392 the upfront cost.

393 Given that the RV3-BB vaccine is not yet available, we also evaluated the cost-394 effectiveness of adding a third dose to the Rotarix vaccine schedule. At a marginally 395 higher cost per DALY averted compared to the current two-dose schedule, a third dose 396 administered at 14 weeks would be cost-effective well below the assumed WTP 397 threshold and is a good option for improving rotavirus vaccine impact in Malawi in the 398 absence of RV3-BB vaccine availability. Administering a third dose at 14 weeks is more favorable than at 40 weeks in our analysis. While the 6/10/40 strategy averted more 399 400 cases overall, and the difference in overall cost is marginal, the 6/10/14 strategy averted 401 more moderate-to-severe cases and, therefore, more DALYs. However, we assumed 402 the probability of responding to the third dose is the same at 14 and 40 weeks. Children 403 who failed to respond to the first two doses may be more likely to respond to a third 404 dose administered later due to less interference from maternal antibodies, co-405 administered oral polio vaccines, better nutritional status, or other factors impacting the 406 immune response (33, 34). There is very little clinical research on the benefits of more 407 than two doses of Rotarix, and most available studies compared the three-dose findings 408 with a 10/14 schedule, not a 6/10 schedule(35). In Ghana, a randomized control trial 409 found that adding a third dose at 14 weeks resulted in greater seroconversion than the 410 two-dose schedule alternatives(8). Another clinical trial conducted in Malawi found that 411 a third dose reduced RVGE incidence, although it was not powered to detect any 412 differences(13). A 6/10/40 schedule may improve the chances that children respond to

It is made available under a CC-BY 4.0 International license .

413 vaccination, although it would prevent RVGE in older children in whom the disease414 tends to be less severe.

415 Three other vaccines on the market are administered in three-dose schedules. 416 two of which are cheaper per dose than Rotarix(17, 36). We did not consider these less 417 expensive three-dose vaccines for comparison to the Rotarix schedules because there 418 is no robust evidence on how the vaccine effectiveness of each of these three-dose 419 vaccines compares to two-dose Rotarix. Assuming the other rotavirus vaccines' 420 effectiveness was comparable to the modeled impact of the three-dose Rotarix 421 schedule, we may find other vaccines on the market are more cost-effective than the current two-dose schedule simply because they are cheaper. 422

423 While adding a third dose to the Rotarix schedule is not as cost-effective as 424 switching to the neonatal vaccine, it may be more organizationally feasible and cost less 425 upfront. Minimal training would be required to use the same vaccine. Other routine EPI vaccines, such as OPV and DTP, begin at six weeks, typically with 4-week intervals 426 427 between two or more subsequent doses, so most patients are already returning for a 428 vaccine appointment around 14 weeks of age(37). In the face of vaccine hesitancy, this 429 strategy also maintains the use of a vaccine that caretakers are already familiar with 430 and has been used for over a decade in Malawi. Given concerns about OPV 431 interference with rotavirus vaccine response, future analyses could consider dosing 432 schedules matching other routine immunizations, such as the new malaria vaccine at 22 433 weeks.

The results of this analysis should be considered with some limitations in mind.
While many parameters for the cost-effectiveness analysis were specific to Malawi,

It is made available under a CC-BY 4.0 International license .

436 values such as healthcare-seeking probabilities for those with RVGE were based on 437 global estimates or derived from data from other countries. In addition, the estimated 438 CFR for outpatients is unknown and was assumed to be some fraction of the inpatient 439 CFR due to a lack of available data. The model assumed that non-severe RVGE cases 440 do not incur any inpatient costs when, in reality, this may not be the case. Similarly, 441 intussusception, a potential side effect of both vaccines (although RV3-BB may have 442 lower risk) that occurs very rarely, was not considered in our analysis, and the final 443 costs did not include the resulting cost of treatment for these cases(38). Most 444 parameters were specific to Malawi or eastern sub-Saharan Africa and may not reflect 445 other populations' disease dynamics, costs, or health-seeking behaviors.

446 This analysis also combined moderate and severe cases of RVGE into one 447 group to compare to non-severe cases. It assumed that they seek healthcare at the 448 same rates, incur the same cost of treatment, and have the same duration of infection 449 and DALY weight. As a result, the reported costs and outcomes may not accurately 450 reflect the actual values. If a vaccine strategy prevents more severe cases with higher 451 treatment costs than moderate cases from occurring, this analysis may not reflect the greater savings. We have taken measures to manage these limitations responsibly, 452 453 choosing conservative base values whenever possible and conducting extensive 454 sensitivity analyses.

This country-level analysis provides a framework for considering new rotavirus vaccine options where a program is already in place, although more research is needed to understand how these strategies and others not considered in this analysis compare in other settings. Using a validated model of rotavirus disease dynamics and country-

459	specific cost data, this study predicted the RV3-BB neonatal vaccine would be highly
460	cost-effective and may offer solutions to low vaccine efficacy in Malawi and other
461	LMICs. In the absence of the RV3-BB vaccine, adding a third dose of Rotarix at 14
462	weeks to the current two-dose schedule is likely a cost-effective strategy to further
463	reduce the rotavirus burden. Routine vaccination is critical to reducing disease and
464	deaths due to rotavirus overall and can lead to financial savings in the long run. As
465	decision-makers consider new vaccine strategies to improve rotavirus prevention
466	efforts, these results can inform how employing innovative vaccine strategies may
467	provide additional impact and be cost-effective in Malawi.
468	
469	Code availability
470	Code for the model and analysis was written and implemented in R v4.3.1 (R Core
471	Team, 2023) and is available at https://github.com/CatherineWenger/RotavirusCEA-
472	Malawi.
473	
474	S1 Checklist. CHEERS 2022 checklist.
475	(DOCX)
476	File Name: CHEERS_Checklist.docx
477	
478	S1 Appendix. Supplementary descriptions and figures.
479	Fig S1. Diagram of Transmission-Dynamic Model.
480	Table S1. The fixed, fitted, and estimated parameter definitions and their sources for the
481	dynamic model.

482 Table S2. Outcomes by Vaccine Schedule. T

- 483 able S3. Outcomes Averted by Vaccine Schedule.
- 484 Fig S2. Cost-effectiveness plane for the cost-effectiveness ratios of the Rotarix
- 485 strategies compared to no vaccination from the government perspective.
- 486 Table S4. The dosing schedules, the number of doses, and the age of vaccination.
- 487 Table S5. Cost-Effectiveness Comparison of All Vaccine Strategies.
- 488 Fig S3. Cost-effectiveness plane for the cost-effectiveness ratios of the four strategies
- 489 compared to the current Rotarix 6/10 schedule from the societal perspective.
- 490 Fig S4. Cost-effectiveness acceptability curves and frontiers.
- 491 Table S6. Cost-Effectiveness Comparison of Available Vaccine Strategies.
- 492 Fig S5. Cost-effectiveness plane for the cost-effectiveness ratios of the Rotarix
- 493 strategies compared to no vaccination from the societal perspective.
- 494 Fig S5. Sensitivity analyses of the price per dose of the RV3-BB neonatal vaccine
- 495 compared to the current Rotarix schedule and the optimal three-dose Rotarix schedule
- 496 from the societal perspective.
- 497 (DOCX)
- 498 File Name: RotaCEA\_Supp.docx

499

505

### 508 References

509 1. Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination.

510 Gastroenterology. 2009;136(6):13.

511 2. Du Y, Chen C, Zhang X, Yan D, Jiang D, Liu X, et al. Global burden and trends of

rotavirus infection-associated deaths from 1990 to 2019: an observational trend study.
Virology Journal. 2022;19(166):10.

514 3. Collaborators GDD. Estimates of global, regional, and national morbidity, mortality,

and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of
 Disease Study 2015. Lancet Infectious Disease. 2017;17:40.

4. Janko MM, Joffe J, Michael D, Earl L, Rosettie KL, Sparks GW, et al. Cost-

effectiveness of rotavirus vaccination in children under five years of age in 195 countries: Ameta-regression analysis. Vaccine. 2022;40:15.

520 5. Strategic Advisory Group of Experts. Rotavirus vaccines: an update. World Health 521 Organization.

522 6. Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA,

523 Thakkinstian A. Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus

524 Vaccine in Low-Income and Lower-Middle-Income Countries. Open Forum Infectious525 Diseases. 2019:11.

526 7. Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, et al. Rotavirus Vaccination
527 and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA
528 Pediatrics. 2018;172(10):16.

529 8. Armah G, Lewis KDC, Cortese MM, Parashar UD, Ansah A, Gazley L, et al. A

530 Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune

Response to Human Rotavirus Vaccine in Rural Ghanaian Infants. The Journal of Infectious
Diseases. 2016;213:8.

9. Pitzer VE, Ndeketa L, Asare EO, Hungerford D, Lopman BA, Jere KC, et al. Impact of
rotavirus vaccination in Malawi from 2012 to 2022 compared to model predictions. npj
Vaccines. 2024;9(227).

536 10. Bennett A, Pollock L, Jere KC, Pitzer VE, Parashar U, Tate JE, et al. Direct and
537 possible indirect effects of vaccination on rotavirus hospitalisations among children in
538 Malawi four years after programmatic introduction. Vaccine. 2018;36:7.

539 11. Pitzer VE, Bennett A, Bar-Zeev N, Jere KC, Lopman BA, Lewnard JA, et al. Evaluating
 540 strategies to improve rotavirus vaccine impact during the second year of life in Malawi.

- 541 Science Translational Medicine. 2019;11:12.
- 542 12. Witte D, Handley A, Jere KC, Bogandovic-Sakran N, Mpakiza A, Turner A, et al.

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant
 administration schedule in Malawi: a randomised, double-blind, four-arm parallel group
 dose-ranging study. Lancet Infectious Disease. 2022;22:11.

546 13. Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, et al. Efficacy of

547 human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two

548 years of life: a randomised, double-blind, placebo controlled trial. Vaccine. 2012;30(1):16.

549 Omore R, O'Reilly CE, Williamson J, Moke F, Were V, Farag TH, et al. Health Care-14. 550 Seeking Behavior During Childhood Diarrheal Illness: Results of Health Care Utilization and Attitudes Surveys of Caretakers in Western Kenya, 2007–2010. American Journal of Tropical 551 552 Medicine. 2013;89:12. 553 15. Omore R, Khagayi S, Ogwel B, Onkoba R, Ochieng JB, Juma J, et al. Rates of 554 hospitalization and death for all-cause and rotavirus acute gastroenteritis before rotavirus 555 vaccine introduction in Kenya, 2010–2013. BMC Infectious Diseases. 2019;19(47):11. 556 Asare EO, Hergott D, Seiler J, Morgan B, Archer H, Wiyeh AB, et al. Case fatality risk 16. 557 of diarrhoeal pathogens: a systematic review and meta-analysis. International Journal of 558 Epidemiology. 2022;00:12. 559 Rotavirus vaccine (RV) price data: UNICEF; 2024 [updated 22 February 2024. 17. 560 Available from: https://www.unicef.org/supply/documents/rotavirus-vaccine-rv-price-data. 561 Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, et al. 18. 562 Developing a manufacturing process to deliver a cost effective and stable liquid human 563 rotavirus vaccine. Vaccine. 2021;39:12. 564 Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, Shamsuzzaman M, et al. 19. 565 Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, 566 Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018;36:7. 567 Owusu R, Mvundural M, Nonvignonl J, Armah G, Bawa J, Antwi-Agyei KO, et al. 20. 568 Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, 569 switching costs, and cost-effectiveness. PLOS Global Public Health. 2023;3(8):17. 570 Wolfson LJ, Gasse Fo, Lee-Martin S-P, Lydon P, Magan A, Tibouti A, et al. Estimating 21. 571 the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-572 2015. Bulletin of the World Health Organization. 2008;86(1):13. 573 22. Bar-Zeev N, Tate JE, Pecenka C, Chikafa J, Mvula H, Wachepa R, et al. Cost-574 Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction 575 Analysis Using Individual Patient-Level Costing Data. Clinical Infectious Diseases. 2016;62:9. 576 Life expectancy at birth, total (years) - Malawi: World Bank; 2021 [Available from: 577 23. 578 https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=MW. 579 GDP per capita - Malawi: World Bank; 2022 [Available from: 24. 580 https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MW. 581 Department of Immunization Vaccines and Biologicals. WHO Guide on 25. 582 Standardization of Economic Evaluations of Immunization Programmes. Geneva; 2019 583 October 2019. 584 26. Claxton K, Martin S, Soares M, al. e. Methods for the estimation of the National 585 Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment. 19. Southampton, UK: NIHR Journals Library; 2015. 586 587 Edlin R, McCabe C, Hulme C, Hall P, Wright J. Probability Distributions for Cost and 27. 588 Utility Parameters. Cost Effectiveness Modelling for Health Technology Assessment: Adis, 589 Cham; 2015. 590 Michael Drummond, Mark Sculpher, George Torrance, Bernie O'Brien, Stoddart G. 28. 591 Cost-Effectiveness Analysis. Methods for the Economic Evaluation of Health Care 592 Programmes. Third ed. Oxford, UK: Oxford University Press; 2005. p. 34.

593 29. Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, YL. C. The Use of Cost-

594 Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income 595 Countries From 2015 to 2020: A Review. Value Health. 2022;25(3):5.

- 596 30. Debellut Fdr, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, et al. Re-evaluating
- the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a
- 598 modelling study. Lancet Global Health. 2019;7:11.
- 599 31. PATH. PATH announces early closure of pivotal Phase 3 study of an injectable 600 rotavirus vaccine candidate: PATH; 2022 [updated 30 August 2022. Available from:
- 601 <u>https://www.path.org/our-impact/media-center/path-announces-early-closure-of-pivotal-</u>
- 602 phase-3-study-of-an-injectable-rotavirus-vaccine-
- 603 <u>candidate/#:~:text=and%20institutional%20foundations.-,PATH%20announces%20early%</u>
- 604 20closure%20of%20pivotal%20Phase%203,an%20injectable%20rotavirus%20vaccine%2
- 605 <u>Ocandidate&text=The%20trial%20aimed%20to%20determine,vaccine%20in%20preventin</u>
- 606 g%20infant%20diarrhea.
- 607 32. Health Sector Strategic Plan II (2017-2022). In: Health Mo, editor.: Governemnt of608 the Republic of Malawi; 2017. p. 122.
- 609 33. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus
- vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200 Suppl1(0 1):S39-48.
- 612 34. Folorunso OS, Sebolai OM. Overview of the Development, Impacts, and Challenges
  613 of Live-Attenuated Oral Rotavirus Vaccines. Vaccines (Basel). 2020;8(3).
- 614 35. Gruber JF, Gruber LM, Weber RP, Becker-Dreps S, Funk MJ. Rotavirus Vaccine
- 615 Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A
- 616 Systematic Review. Open Forum Infectious Diseases. 2017:10.
- 617 36. Rotavirus vaccines: WHO position paper July 2021. World Health Organization;
  618 2021 16 July 2021.
- 619 37. WHO. WHO recommendations for routine immunization summary tables. World620 Health Organization; 2023.
- 621 38. Bines JE, Thobari JA, Satria CD, Handley A, Watts E, Cowley D, et al. Human
- 622 Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. The New England
- 623 Journal of Medicine. 2018;378(8):12.
- 624





#### Cost-Effectiveness Plane Government Perspective - Strategies Compared to Rotarix 6/10





Sensitivity Analysis of RV3 Price

**a.** Comapred to Rotarix 6/10, Government Perspective



**b.** Sensitivity Analysis of RV3 Price Comapred to Rotarix 6/10/14, Government Perspective